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Introduction
Ataxia telangiectasia mutated and RAD3-related protein (ATR) is a serine/threonine protein kinase that forms part of the DNA-damage response (DDR) coordinating the cellular response to DNA damage, stress, and cell-cycle perturbation (Cimprich and Cortez, 2008) and has become an attractive therapeutic target in cancer therapy (Foote et al., 2015; Weber and Ryan, 2015) . AZD6738
( fig 1) is a selective and potent inhibitor of ATR, is orally active and bioavailable Jones et al., 2013) and has been taken into clinical development (ClinicalTrials.gov Identifier: NCT02223923; NCT02630199; NCT01955668; NCT02264678).
From a structural and metabolic perspective, the key functional group of interest is the sulfoximine moiety. A recent review by Sirvent and Lucking (2017) has highlighted that sulfoximines are being increasingly used in drug discovery as well as in clinical candidates. Beyond AZD6738, roniciclib and BAY 1143572 both contain sulfoximine moieties. The authors point out that sulfoximines have a unique set of physico-chemical and hydrogen bonding properties that make it a moiety of utility for medicinal chemistry and show this by replacing either secondary or tertiary amines with sulfoximines into a set of clinical compounds and comparing pharmacological, physico-chemical and drug metabolism properties. The sulfoximine analogues had similar pharmacological potencies and lipophilicities despite an increased degree of hydrogen bonding. This work highlights that although the drug analogues that were made showed generally better metabolic stabilities, there is little known about the metabolism of sulfoximines. Roniciclib is in clinical trials as a pan-CDK inhibitor with reportedly favourable pharmacokinetic properties in preclinical species but to date there is no published metabolism information on this compound (Bahleda et al., 2017) .
Buthionine sulfoximine is an inhibitor of glutamylcysteine synthetase and is used in cancer chemotherapy to deplete glutathione and so make cells vulnerable to reactive oxygen species This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on September 6, 2017 dmd.aspetjournals.org Downloaded from DMD # 77776 5 (Glasauer and Chandel, 2014) . Despite many years of clinical use there is very little information on its metabolism. The information that does exist shows that the compound is excreted largely unchanged in the urine with a small amount of an acylated metabolite also being formed (Ahluwalia et al., 1990) . Thus there is no information on the metabolic fate of the sulfoximine.
Once a metabolic route has been defined, reaction phenotyping studies are now routinely carried out to define what proportion of the route is mediated by different enzymes. Generally these studies comprise a number of different parts which can include inhibition with specific inhibitors, metabolism by recombinant enzymes and correlation with specific probe substrate activities across a panel of different biological samples (Zientek and Youdim, 2015) . This approach has been used to understand the contribution of CYP and non CYP enzymes to metabolic transformations (Argikar et al., 2016) .
The aim of the current study was to characterise the in vitro metabolism of AZD6738, particularly as it relates to the sulfoximine moiety and to conduct reaction phenotyping studies to understand the fate of this group and the enzymes involved.
This article has not been copyedited and formatted. The final version may differ from this version. Microsomal, S9, cytosol and recombinant enzymes incubation conditions: Metabolic studies in human liver S9 (1mg/ml), cytosol (1mg/ml), HLM (0.5mg/ml); recombinant CYPs (100pmol/ml), recombinant FMOs (0.25mg/ml) and NADPH CYP-reductase bactosomes (100pmol/ml) were conducted in the presence of 1mM NADPH, mixed with 0.1M phosphate buffer pH7. sulfoxide and sulfone calibration curves were generated in the relevant matrices with a limit of detection for both the sulfoxide and sulfone of 1nM. In all experiments, the final solvent concentration was always <0.1% DMSO and <1% ACN.
Instrumentation: All LC-MS/MS data was acquired on a Waters Xevo® TQ-S mass spectrometer
connected to a Waters Acquity UPLC (Ultra high-Performance Liquid Chromatography). The Waters Acquity system consisted of an autosampler, binary UPLC PUMP, column oven, autoinjector and a photodiode array detector. The analytes were separated by reverse-phase liquid chromatography using Kinetex C18 (50 x 2.1 mm, 2.6 µm, Phenomenex, Macclesfield, UK) preceded by a guard filter in a column oven at 50ºC. The mobile phase consisted of high performance liquid chromatography (HPLC) grade water with 0.1% formic acid (eluent A) and MeOH with 0.1% formic acid (eluent B). The elution profile was: linear gradient 95% A to 5% A, 0.00 to 2.2 minutes; isocratic hold, 5% A 2.2 minutes to 2.6 minutes; re-equilibration 95% A, 2.61 minutes to 2.8 minutes. The flow rate was 0.6 ml/min and the eluent was introduced into the mass spectrometer via the divert valve at 0.5 minutes. The injection volume was 3uL. The Xevo TQ-S was equipped with an electrospray ionisation (ESI) source, which was operated in positive mode. The mass spectrometer source settings were as following: the capillary voltage was 0.7kV and source offset was 59V. The
This article has not been copyedited and formatted. The final version may differ from this version. DMD # 77776 9 desolvation temperature was set to 600°C. Nitrogen was used as the desolvation gas (1000L/Hr) and cone gas (150L/Hr). Argon was used as the collision gas at a flow rate of 0.15 ml/min. Detection of the ions was performed in the multiple reaction monitoring (MRM) mode using the transitions described in Table 1 . Peak integration and calibrations were performed using TargetLynx software (Version 4.1, Waters, Milford, MA).
The structures of AZD6738, the sulfoxide metabolite AZ8982 and the sulfone metabolite AZ0002 are
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Results
Preliminary characterisation
AZD6738 was incubated in different human hepatic S9 cytosol and microsomal fractions at a concentration of 1µM to determine the nature of enzyme mediating the de-imination (fig 2) .
In S9 AZD6738 was metabolised to the sulfoxide (AZ8982) and the sulfone (AZ0002) in the presence of NADPH. In the absence of NADPH there was no apparent formation of either of these metabolites. In the presence of NADPH the rate of formation of AZ133682982 was 0.3pmol/min/mg whilst the rate for AZ0002 was lower at 0.16pmol/min/mg (fig 2) .
There was no apparent formation of either metabolite in cytosol ruling out the involvement of soluble enzymes such as aldehyde and xanthine oxidase.
When AZD6738 (1µM) was incubated with HLM in the presence of NADPH the formation of both AZ8982 and the corresponding sulfone AZ0002 was observed. In the absence of NADPH there was no measureable formation of either metabolite. Similarly under anaerobic conditions there was no measurable formation of either metabolite compared to control incubations carried out under aerobic conditions. Pre-incubation with 1mM aminobenzatriazole (ABT) under aerobic conditions significantly reduced the rate of formation of both AZ8982 and AZ0002 by more than 80% for both metabolites (fig 2) .
This article has not been copyedited and formatted. The final version may differ from this version. These preliminary studies strongly suggested that the de-imination was not a reductive process but rather an oxidative one mediated by enzymes in the microsomal fraction such as either CYPs or FMOs.
HLM enzyme kinetics
The enzyme kinetics of the de-imination of AZD6738 was investigated in pooled HLM by following the rate of formation of AZ8982 over an AZD6738 concentration range. Initial studies at 1µM
AZD6738 showed that the rate of formation was linear with protein and time up to 0.5mg/ml and 30 minutes respectively. These conditions were used in the enzyme kinetic study over an AZD6738 concentration range of 0.5 to 200µM (fig 3) .
The de-imination showed saturable kinetics with a Km of 137µM and a Vmax of 18pmol/min/mg protein. This provides further support to the de-imination being an enzymatic rather than chemical process.
Recombinant CYP studies
The rate of metabolism was studied a panel of 11 recombinant CYPs -CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 CYP2J2, CYP3A4 and CYP3A5 at an AZD6738 concentration of 1µM ( fig 4A) .
Of the enzymes studied only CYP3A4 and CYP3A5 produced CLint values of 0.177µl/min/pmol CYP and 0.04µl/min/pmol CYP respectively. However, AZ8982 was only detected being formed by CYP2C8 and CYP2J2 at rates of 0.74 and 0.16pmol/min/pmol CYP respectively. This suggests that although CYP3A has the ability to metabolise AZD6738 only CYP2C8 and CYP2J2 are responsible for forming AZ8982.
In addition, the rate of metabolism was also investigated in recombinant FMO3, FMO5 and NADPH cytochrome C reductase to see if either of these enzymes were also playing role. None of these enzymes showed any metabolic activity towards AZD6738 either in terms of disappearance or AZ8982 formation.
AZ8982 was also incubated with the same panel of recombinant of CYPs with CYP3A4 and CYP3A5 again producing the highest CLint values of 2.7 and 0.5µl/min/pmol CYP respectively (fig 4B). These were followed by CYP2J2 and CYP2C8 with CLints of 0.4 and 0.05µl/min/pmol CYP respectively.
However, in this case the enzymes were responsible for producing the sulfone were also CYP2J2, CYP2C8, CYP3A4 and CYP3A5 with rates of 0.34, 0.03, 0.17 and 0.16pmol/min/pmol CYP respectively indicating a stronger relationship between the CLint and formation of the sulfone than was seen for the initial de-imination.
Hence the recombinant enzymes confirm the de-imination of AZD6738 as an oxidative process which is mediated by CYP2C8 and CYP2J2. In addition, the subsequent oxidation to the sulfone (AZ0002) is catalysed by CYP2J2, CYP2C8, CYP3A4 and CYP3A5.
Silensomes TM studies
To elucidate the enzymes involved in the de-imination of AZD6738 the formation of AZ8982 was studied in CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 Silensomes TM (fig 5) . Given the high Km previously determined these studies were conducted at 25µM AZD6738.
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The data from the previous HLM and rCYP studies suggest that the apparent increase in the rate of formation of AZ8982 formation in CYP3A4 Silensomes TM was due, in fact, to inhibition of the subsequent metabolic step (the formation of AZ0002) causing a build-up of the sulfoxide. This supports the hypothesis that the de-imination is the initial metabolic step which is followed by oxidation to the sulfone. This was confirmed by measuring the CLint for AZ8982 in Silensomes TM CYP3A4 and CYP2C8 and showing a 97% and 10% reduction respectively (data not shown).
Correlation analysis
The rate of formation of AZ8982 from AZD6738 at 25µM was studied in set of 7 HLM samples from individual samples along with the pooled HLM sample used in the previous studies. In addition, (table 2) . There was a poor correlation with the majority of the enzyme activities with the correlation coefficients determined as being less than 0.5.
The most significant correlation (correlation coefficient = 0.73) was seen between the rate of formation of AZ8982 and the CYP2C8-mediated rate of N-deethylation of amidiaquine (fig 6) ..
This further supports to the previous data which shows that in HLM the de-imination of AZD6738 is an oxidative process mediated primarily by CYP2C8.
Discussion
Reaction phenotyping is now a relatively routine activity conducted during the discovery and development of drugs. It involves a well-defined set of studies usually including a combination of metabolite formation by recombinant enzymes, inhibition by specific inhibitors and correlation across different biological samples which have been characterised for different enzyme activities (Zientek and Youdim, 2015) . In the context of this study, reaction phenotyping has been used to understand the de-imination of AZD6738.
This study has investigated the de-imination of AZD6738 to its sulfoxide metabolite (AZ8982). It has shown that this is an oxidative process mediated by cytochrome P450. Following this reaction phenotyping studies including recombinant enzymes, inhibitor (Silensomes TM ) and correlation studies identified CYP2C8 as the major CYP involved in this biotransformation. The sulfone metabolite, AZ0002, was also observed in these studies but the data suggest that this is a subsequent reaction following the de-imination and is mediated by CYP3A.
CYP2J2 was also shown to have a role in the de-imination of AZD6738. However, there is a relatively low level of expression of this enzyme in human liver (around 1.2pmol/mg protein), which equates to 0.3% of the total hepatic cytochrome P450 content (Achour et al., 2014) . When compared with CYP2C8 which has an expression level of around 22pmol/mg, which in turn equates to around 5% total hepatic cytochrome P450 content, it is clear that CYP2J2 would be a minor contributor to the hepatic de-imination of AZD6738.
Interestingly CYP3A did not play a significant role in the de-imination of AZD6738. The recombinant CYP CLint data show that there was metabolism of AZD6738 by CYP3A but this did not include the formation of the sulfoxide. This finding was supported by the Silensomes TM and correlation data. However, CYP3A was the major enzyme involved in the formation of the sulfone (AZ0002). Based on the data from these studies it is possible to suggest that this is a subsequent step to the initial deimination rather than being formed directly from AZD6738.
CYP2C8 is increasingly recognised as a key human drug metabolising enzyme. AZD6738 can now be added to the increasing list of CYP2C8 substrates which include compounds such as cerivastatin, montelukast and rapaglinide (Backman et al., 2016) . In addition, like AZD6738, there are a number of anti-cancer agents on the substrate list including paclitaxel, imatinib and tozasertib. Unlike CYP2C9
and CYP2D6, CYP2C8 does not appear to have a characteristic substrate recognition motif such as an acidic or basic function although pharmacophore models for CYP2C8 have been proposed that involve a combination of hydrophobic and polar functions at fixed distances from the site of metabolism (Melet et al., 2004) . Whilst AZD6738 may have many of the structural features which align with this type of pharmacophore model, it is difficult to rationalise why the sulfoxide should not be metabolised by the same enzyme but is preferentially metabolised by CYP3A.
There does seem to be a significant overlap between substrates of CYP2C8 and CYP3A (Backman et al., 2016) . However, the x-ray crystal structures have revealed that the active sites have a similar size 1438Å 3 for CYP2C8 and 1386Å 3 for CYP3A but have different shapes. The active site of CYP3A is generally thought of being a large open space whereas the CYP2C8 active site has been described as being T or V shaped (Backman et al., 2016 ). However, these high level structural differences do not explain why CYP2C8 is able to mediate the de-imination of AZD6738 when CYP3A4 cannot as it is likely that AZD6738 will fit into both these active sites. In the absence of co-crystal structures of AZD6738 with CYP2C8 and CYP3A4 it is not possible to shed any further light on the differences observed with the selectivity of the de-imination reaction.
This article has not been copyedited and formatted. The final version may differ from this version. Having identified CYP2C8 as the major enzyme involved in the de-imination of AZD6738, the question becomes what is the mechanism for this reaction. Nominally going from a sulfoximine to a sulfoxide is a reductive reaction but the data detailed here shows it to actually be an oxidation. This is a kin to the well described deamination reaction mediated by cytochrome P450s seen with compounds such as diltiazem (Nakamura et al., 1990) . However, the mechanism for this reaction is generally described as proceeding via oxidation of the alpha carbon atom adjacent to the nitrogen.
In the case of AZD6738 there is no carbon atom adjacent to the imine nitrogen so this mechanism is unlikely. One other potential mechanism would be similar to the proposed mechanism for Noxidation (Guengerich, 2001) but in this case after the initial oxidation of the imine nitrogen there is potential for a subsequent oxidation and the liberation of nitrous acid to yield the sulfoxide (fig 7) .
In summary, these in vitro studies show that AZD6738 undergoes oxidative de-imination to the corresponding sulfoxide (AZ8982) mediated principally by CYP2C8. AZ8982 undergoes subsequent CYP3A-mediated oxidation to the sulfone (AZ0002). This represents one of the first studies into the metabolism of the sulfoximine moiety.
